{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:23:12Z","timestamp":1790022192720,"version":"4.0.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001377","name":"Walther Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08HL106576"],"award-info":[{"award-number":["K08HL106576"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA101937"],"award-info":[{"award-number":["P01CA101937"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA91842"],"award-info":[{"award-number":["P30CA91842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0179558","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T13:28:12Z","timestamp":1500384492000},"page":"e0179558","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":56,"title":["Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia"],"prefix":"10.1371","volume":"12","author":[{"given":"Shovik","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Traer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-6683","authenticated-orcid":true,"given":"Ji-Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref2","first-page":"107","article-title":"Ther Adv Hematol","author":"J Ai","year":"2014"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1185\/03007990903479299","article-title":"Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study","volume":"26","author":"M Michallet","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"N Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref5","first-page":"461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"2009","author":"D Bixby","year":"2009","journal-title":"ASH Education Program Book"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apsb.2011.10.007","article-title":"Mechanisms of acquired resistance to tyrosine kinase inhibitors","volume":"1","author":"Y-f Chen","year":"2011","journal-title":"Acta Pharm Sin B"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL\u2013independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"L Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular Fatty Acid Metabolism and Cancer","volume":"18","author":"E Currie","year":"2013","journal-title":"Cell Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","article-title":"Lipid metabolism in cancer","volume":"279","author":"CR Santos","year":"2012","journal-title":"FEBS J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"JA Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/srep06807","article-title":"Direct Visualization of De novo Lipogenesis in Single Living Cells","volume":"4","author":"J Li","year":"2014","journal-title":"Scientific Reports"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10549-009-0594-8","article-title":"High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation","volume":"122","author":"C Antalis","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2184.2011.00758.x","article-title":"Cholesterol esters as growth regulators of lymphocytic leukaemia cells","volume":"44","author":"MF Mulas","year":"2011","journal-title":"Cell Prolif"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4161\/cbt.9.12.11875","article-title":"Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines","volume":"9","author":"S Bemlih","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1038\/onc.2016.168","article-title":"Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer","volume":"35","author":"J Li","year":"2016","journal-title":"Oncogene"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","article-title":"Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K\/AKT Activation Underlies Human Prostate Cancer Aggressiveness","volume":"19","author":"S Yue","year":"2014","journal-title":"Cell Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1021\/nn504025a","article-title":"Avasimibe Encapsulated in Human Serum Albumin Blocks Cholesterol Esterification for Selective Cancer Treatment","volume":"9","author":"SS-Y Lee","year":"2015","journal-title":"ACS Nano"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4161\/cbt.9.12.11875","article-title":"Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines","volume":"9","author":"S Bemlih","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"0007439","DOI":"10.1371\/journal.pone.0007439","article-title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice","volume":"4","author":"KJ Johnson","year":"2009","journal-title":"PLoS ONE"},{"key":"ref20","first-page":"7149","article-title":"Activity of the Bcr-Abl Kinase Inhibitor PD180970 against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI571)","volume":"62","author":"P La Ros\u00e9e","year":"2002","journal-title":"Cancer Res"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"E Traer","year":"2014","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"T-C Chou","year":"2010","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum","volume":"332","author":"SC Bendall","year":"2011","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"E-aD Amir","year":"2013","journal-title":"Nat Biotech"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1021\/jp902231y","article-title":"High-speed vibrational imaging and spectral analysis of lipid bodies by compound Raman microscopy","volume":"113","author":"MN Slipchenko","year":"2009","journal-title":"J Phys Chem B"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","article-title":"Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions","volume":"110","author":"J-C Tardif","year":"2004","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bjp.0704334","article-title":"PKC- and ERK-dependent activation of I\u03baB kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation","volume":"134","author":"B-C Chen","year":"2001","journal-title":"Br J Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0179558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:13:16Z","timestamp":1588993996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0179558"}},"subtitle":[],"editor":[{"given":"Irina U.","family":"Agoulnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0179558","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]}}}